MYDA Advisors LLC lowered its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 22.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,000 shares of the company's stock after selling 16,000 shares during the period. MYDA Advisors LLC owned about 0.05% of Biohaven worth $2,017,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in shares of Biohaven in the fourth quarter worth about $56,000. Amalgamated Bank grew its position in shares of Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after buying an additional 527 shares during the last quarter. US Bancorp DE increased its stake in shares of Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after buying an additional 798 shares during the period. Elkhorn Partners Limited Partnership raised its holdings in shares of Biohaven by 50.0% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock valued at $123,000 after acquiring an additional 1,100 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Biohaven by 50.1% in the fourth quarter. KBC Group NV now owns 3,377 shares of the company's stock valued at $126,000 after acquiring an additional 1,127 shares in the last quarter. Institutional investors own 88.78% of the company's stock.
Insider Transactions at Biohaven
In other news, Director John W. Childs acquired 32,700 shares of Biohaven stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 16.00% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on BHVN shares. Morgan Stanley dropped their target price on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Biohaven currently has a consensus rating of "Buy" and a consensus target price of $62.77.
Check Out Our Latest Research Report on Biohaven
Biohaven Trading Down 15.2 %
BHVN stock traded down $3.55 during midday trading on Friday, hitting $19.85. The company's stock had a trading volume of 4,084,459 shares, compared to its average volume of 1,125,082. The firm's 50-day moving average is $26.83 and its 200-day moving average is $37.83. Biohaven Ltd. has a 12 month low of $15.79 and a 12 month high of $55.70. The company has a market cap of $2.03 billion, a PE ratio of -2.15 and a beta of 1.33.
Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). Analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current year.
About Biohaven
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Further Reading
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
